Hypoxic-immune Model Based on Lung Squamous Cell Carcinoma Reveals the Effects of Inflammation and Hypoxia on Drug Resistance, CD8 Cell Depletion and Prognosis
Abstract Background: Lung squamous cell carcinoma (LUSC) is a malignant tumor with high mortality and poor prognosis. More evidence shows that hypoxia and the immune environment play an essential role in cancer progression, but the specific impact on lung squamous cell carcinoma is unclear. This study mainly establishes immune and hypoxia risk models to predict the prognosis of patients and formulates personalized treatment plans for patients according to the specific conditions of hypoxia regulation and immune invasion in high-risk groups. Results: Based on the combined use of multiple data, 380 hypoxia and immune co-related genes (HMGs) were obtained, to establish the risk model of immune and hypoxia. Through the use of comprehensive analysis methods, the model has a high predictive value. The survival rate of the high-risk group is low, and the CD8-T cell depletion factor is widely distributed in high-risk groups. It has a large number of neutrophils and low CD8 cells. In addition, hypoxia, inflammation, and drug resistance-related pathways are also abundant in high-risk groups. We also found that high-risk patients were generally resistant to chemotherapeutic drugs. Finally, we constructed a competing endogenous RNA (CeRNA) network closely related to risk genes, including 9 mRNAs, 10 MicroRNAs (miRNAs), and 16 long non-coding RNAs (lncRNAs). Conclusions:This study specifically analyzed the effects of hypoxia regulation and immune Infiltration on the prognosis of patients. It provided a new idea for patients to improve the prognosis and personalized treatment.